
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Cell Int</journal-id><journal-title-group><journal-title>Cancer Cell International</journal-title></journal-title-group><issn pub-type="epub">1475-2867</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">33013202</article-id><article-id pub-id-type="pmc">7528477</article-id><article-id pub-id-type="publisher-id">1573</article-id><article-id pub-id-type="doi">10.1186/s12935-020-01573-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Primary Research</subject></subj-group></article-categories><title-group><article-title>MicroRNA-138-5p targets the NFIB-Snail1 axis to inhibit colorectal cancer cell migration and chemoresistance</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Weifeng</given-names></name><address><email>zlyyxuwf4194@zzu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Beibei</given-names></name><address><email>zlyychenbb1429@zzu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ke</surname><given-names>Dianshan</given-names></name><address><email>kds8810@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9708-7821</contrib-id><name><surname>Chen</surname><given-names>Xiaobing</given-names></name><address><email>xiaobingchen01@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.414008.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1799 4638</institution-id><institution>Department of Medical Oncology, </institution><institution>The Affiliated Cancer Hospital of Zhengzhou University, </institution></institution-wrap>127 Dong Ming Road, Zhengzhou, 450008 Henan People&#x02019;s Republic of China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.284723.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 8877 7471</institution-id><institution>Department of Cell Biology, </institution><institution>Southern Medical University, </institution></institution-wrap>510515 Guangzhou, Guangdong China </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>20</volume><elocation-id>475</elocation-id><history><date date-type="received"><day>5</day><month>8</month><year>2020</year></date><date date-type="rev-recd"><day>19</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par11">Colorectal cancer ranks among the most lethal diseases worldwide. Although much progress has been made in research and treatment of colorectal cancer in recent years, the underlying mechanisms related to migration of the cancer cells and the reason for chemoresistance still remain unclear. In this research, we explored the underlying effect of miR-138-5p in colorectal cancer.</p></sec><sec><title>Methods</title><p id="Par12">We used qRT-PCR to investigate the expression of miR-138-5p, Snail1, NFIB in colorectal cancer cells. Lentiviral vectors containing miR-138-5p mimics and inhibitors were constructed and transfected cells. Wound healing assay was applied to illustrate interferences on cell migration. Fluorouracial, doxorubicin, cisplat in were used to detect chemotherapy resistance. In order to identify target genes, bioinformatic methods were applied. Snail1 and NFIB protein expression in stable cell lines was detected using Western blot. Double luciferase and CHIP experiment were used to verify binding sites. We used rescue experiments to further explore the interactions among Snail1, NFIB and miR-138-5p.</p></sec><sec><title>Results</title><p id="Par13">The expression of miR-138-5p in colorectal cancer cells was low. miR-138-5p inhibited cell migration in colorectal cancer, and could negatively regulate chemotherapy resistance. miR-138-5p targeted NFIB, and regulated Snail1 expression, which mediated colorectal cancer cell migration and chemotherapy resistance.</p></sec><sec><title>Conclusions</title><p id="Par14">Our research indicates that miR-138-5p could be a crucial modulator controlling colorectal cancer cell migration and chemoresistance, by acting upon the NFIB-Snail1 axis. miR-138-5p has an emerging prospect to be exploited as a new target for colorectal cancer.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Colorectal carcinoma</kwd><kwd>NFIB-Snail1</kwd><kwd>Migration</kwd><kwd>Chemoresistance</kwd><kwd>miR-138-5p</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par19">Cancer is in the forefront of threatening the public health globally [<xref ref-type="bibr" rid="CR1">1</xref>]. Colorectal carcinoma ranks the fourth among the most lethal types. Smoking, alcohol, lack of exercise, and overweight are contributing factors to the genesis and poor prognosis of colorectal cancer. Its morbidity and mortality can be mitigated through proper screening and surveillance [<xref ref-type="bibr" rid="CR2">2</xref>]. Treatments for colorectal cancer include endoscopic and surgical procedures, chemotherapy and radiotherapy [<xref ref-type="bibr" rid="CR3">3</xref>]. Colonic stenting is also a palliative therapy for unresectable colon cancer [<xref ref-type="bibr" rid="CR4">4</xref>]. In order to find better treatment options, it is increasingly important to discover novel molecular targets and mechanisms for colorectal cancer.</p><p id="Par20">miRNAs could modulate several important biological processes, such as regulating the expression of cancer initiative and repressive genes. In recent years, miR-138-5p was found to reduce cancer growth in several cancers [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. For example, research suggested that in pancreatic cancer, miR-138-5p had a suppressing role [<xref ref-type="bibr" rid="CR8">8</xref>]. Gao et al&#x02019;s research showed that through targeting EIF4EBP1, it had an impact on nasopharyngeal cancer radiotherapy [<xref ref-type="bibr" rid="CR9">9</xref>]. Roberto et al. found that the miR-138-5p expression was related to osteosarcoma prognosis [<xref ref-type="bibr" rid="CR10">10</xref>]. Zhao et al. found that by targeting RHBDD1, it could mitigate progression of breast cancer [<xref ref-type="bibr" rid="CR11">11</xref>]. Zhu et al&#x02019;s research showed that it intervened in the development of lung cancer [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par21">In this study, we explored the underlying mechanisms for the roles of miR-138-5p in colorectal cancer migration and chemoresistance. We found that expression of miR-138-5p was lower in colorectal cancer. We also found that miR-138-5p inhibited colorectal cancer cell migration and chemoresistance. NFIB was discovered as a target gene by using bioinformatics methods. NFIB and Snail1 were positively correlated. We subsequently performed knock down experiments to define the interactions among miR-138-5p, NFIB and Snail1. Our research provided new insights towards the treatment of colorectal cancer.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Patients and samples</title><p id="Par22">
This study was approved by the ethics committee of the Affiliated Cancer Hospital of Zhengzhou University. 100 patients diagnosed with colorectal cancer were selected. All patients had read and signed the informed consent. Cancerous tissues and adjacent corresponding normal tissues were obtained. Samples were immediately frozen and stored in the refrigerator at &#x02212;&#x000a0;80&#x000a0;&#x02103;. Clinical and pathological features of 100 patients were presented in the Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par23">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical and pathological features of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Features</th><th align="left">Number of patients</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02266;&#x02009;50</td><td char="." align="char">41</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x02009;50</td><td char="." align="char">59</td></tr><tr><td align="left">Sex</td><td align="left"/></tr><tr><td align="left">&#x000a0;Male</td><td char="." align="char">62</td></tr><tr><td align="left">&#x000a0;Female</td><td char="." align="char">38</td></tr><tr><td align="left">Lymph node status</td><td align="left"/></tr><tr><td align="left">&#x000a0;N0</td><td char="." align="char">55</td></tr><tr><td align="left">&#x000a0;N1</td><td char="." align="char">39</td></tr><tr><td align="left">&#x000a0;N2</td><td char="." align="char">6</td></tr><tr><td align="left">Tumor stage</td><td align="left"/></tr><tr><td align="left">&#x000a0;I&#x02013;II</td><td char="." align="char">79</td></tr><tr><td align="left">&#x000a0;III&#x02013;IV</td><td char="." align="char">21</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Bioinformatic methods</title><p id="Par24">We used miRDB (<ext-link ext-link-type="uri" xlink:href="http://mirdb.org/">http://mirdb.org/</ext-link>) [<xref ref-type="bibr" rid="CR13">13</xref>], DIANA (<ext-link ext-link-type="uri" xlink:href="http://diana.imis.athena-innovation.gr/">http://diana.imis.athena-innovation.gr/</ext-link>) [<xref ref-type="bibr" rid="CR14">14</xref>], TargetScan (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org">www.targetscan.org</ext-link>) [<xref ref-type="bibr" rid="CR15">15</xref>] for predicting target genes. GEPIA (<ext-link ext-link-type="uri" xlink:href="http://gepia.cancer-pku.cn/">http://gepia.cancer-pku.cn/</ext-link>) [<xref ref-type="bibr" rid="CR16">16</xref>] was utilized to verify correlation between NFIB mRNA and Snail1 mRNA.</p></sec><sec id="Sec5"><title>Cell culture</title><p id="Par25">We bought five human colorectal cancer cell lines (LOVO, HCT116, HT29, SW620, SW480) and one normal cell line (FHC) from ATCC (Virginia, USA). All cells were grown in RPMI 1640 (Hy-clone, USA) medium, antibiotics and 100&#x000a0;U/ml penicillin and 100 &#x003bc;g/ml streptomycin 10% fetal serum (FBS, Gipco, USA) were added. The cells were cultured in an incubator at a temperature of 37&#x000a0;&#x000b0;C with 5% CO<sub>2</sub> in a humid atmosphere.</p></sec><sec id="Sec6"><title>qRT-PCR</title><p id="Par26">Total RNA was isolated using TRIzol reagent (Invitrogen Life Technologies, USA) and then was reverse-transcribed into cDNA with the Primer Script RT reagent kit (Takara Bio, China). We used SYBR Green PCR Kit (TAKARA, Japan) to perform qRT-PCR. We used U6 and GAPDH as internal controls. The forward primer for miR-138-5p was: 5&#x02032;-CTAGAGCTCAACTGAAGTGGCTAAACTG -3&#x02032; and reverse primer was 5&#x02032;-GCTAGGCGTTGAAGTTCTGCCTAAATGC-3&#x02032;. The forward primer for NFIB was: 5&#x02032;-GCTGTGTCTTATCCAATCCCG-3&#x02032; and reverse primer was 5&#x02032;-TGCCTTTGAACAGGATCACCA-3&#x02032;. The forward primer for Snail1 was 5&#x02032;-TCGGAAGCCTAACTACAGCGA-3&#x02032;, and reverse primer was 5&#x02032;-AGATGAGCATTGGCAGCGAG-3&#x02032;. The mRNA levels were analyzed using 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method. Three times were replicated for each sample with no RT and no template control.</p></sec><sec id="Sec7"><title>
Western blot</title><p id="Par27">We used 1% PMSF and RIPA lysine buffer to confine cellular protein, then reacted with the SDS-PAGE test buffer. Proteins were transferred to a polyvinylide difluoride layer (Millipur, USA). The layer was grown overnight, after incubation for 1&#x000a0;h, at room temperature. Then we applied the ECL chemiluminescence kit (Advansta, USA), and proteins were fried with secondary antibodies for 1&#x000a0;h. We examined bands using GeneGnome 5 (Synoptics Ltd., UK).</p></sec><sec id="Sec8"><title>Wound healing cell migration assay</title><p id="Par28">We used Oris Cell Migration Kit (Platypus, USA) to assess cell migration. Cells in the 6-well plates grew into full confluence. By scratching the monolayer with a 200-&#x000b5;l plastic pipette tip, a tiny area was disrupted. We washed the cells twice using phosphate-buffer saline (PBS), then replaced using a complete medium, which contained various concentrations of API. We observed wound closure after 48&#x000a0;h. Under a phase-contrast microscope at 100&#x000d7;&#x000a0;magnification, pictures were captured immediately. Cells were washed with PBS.</p></sec><sec id="Sec9"><title>CCK-8 assay</title><p id="Par29">We used cell count-Kit-8 (CCK-8, Dojinto, Japan). We digested the stable strain with 1&#x000a0;ml of 0.25% trypsin. Then it was transferred to a 15&#x000a0;ml centrifugal tube, later it was centrifuged at 1500 rpm for 5&#x000a0;min. We seeded the cells in six-well plates. After 48&#x000a0;h, we detected cell viability using CCK8. In short, 10&#x000a0;&#x000b5;l of 5&#x000a0;mg/ml CCK8 solution was added to the 96&#x02010;well plate. Then it was incubated for 2&#x000a0;h in the dark. In the microplate, the absorbance of each well was measured at 450&#x000a0;nm.</p></sec><sec id="Sec10"><title>Generation of lentiviruses and stable transfection</title><p id="Par30">miR-138-5p mimic and its parallel negative control (mNC), miR-138-5b inhibitor and parallel negative control (inhibitor NC) were purchased from RiboBio (Guangzhou, China). Vectors were transfected, plasmids packaged into cells using Polyget Regent (Signage Labs, USA). After 48 h, virus supernatants were collected. In 12-well plates, cancer cells were spin-infected. Then we centrifuged lentiviral supernatants for half an hour. In order to harvest stable cell lines, cells were selected using puromycin (3&#x000a0;ng/ml). Transient transfections were conducted using Lipofectamine 2000 (Invitrogen, Karlspot, CA, USA).</p></sec><sec id="Sec11"><title>ChIP-seq analysis and dual-luciferase reporter assay</title><p id="Par31">We cross-linked cells using the Qiagen PCR Purification kit. We scraped cell monolayers in soft lysis buffer. Then we lysed nuclei pelletsusing SDS lysine buffer. Protein was diluted 1:10 with dilution buffer and precleared by incubating with protein magnetic beads (Millipore). We immunoprecipitated the samples using the initial antibody. Antibody-chromatin complexes were rescued. Then we washed the beads with buffers. The eluted samples were decrosslinked. Next day, we treated the proteins complexes with proteinase K solution, then incubated them for an hour. We used dual luciferase reporter gene assay kit (Yeasen, China) according to the instruments provided by manufacture.</p></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par32">Data was presented as mean&#x02009;&#x000b1;&#x02009;S.D. We used GraphPad Prism 8.0 software and the SPSS25.0 software to conduct all the statistical analyses. Significant difference between each group was analyzed using unpaired 2-tailed Student&#x02019;s t tests or one-way ANOVA. A <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec13" sec-type="results"><title>Results</title><sec id="Sec14"><title>Expression of miR-138-5p was reduced in colorectal cancer tissues</title><p id="Par33">In 100 colorectal cancer samples, expression of miR-138-5p was significantly reduced (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b illustrated that 8 tumor tissues were high and 92 were low in expression. Then, we analyzed expression of miR-138-5p in colorectal cancer samples with and without lymph node metastasis. Results revealed that expression of miR-138-5p in tissues with lymph node metastasis was low, while expression in samples without lymph node metastasis was high (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). We further detected miR-138-5p expression in normal colonic cells and 5 colorectal cancer cell lines: FW480, HT29, DLD1, HCT116, LOVO. Results revealed that the expression was decreased in the colorectal cancer cell lines (p&#x02009;&#x0003c;&#x02009;0.01) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d).</p><p id="Par34">
<fig id="Fig1"><label>Fig. 1</label><caption><p>
Expression of miR-138-5p was reduced in colorectal cancer tissues. <bold>a</bold> miR-138-5p expression was low in colorectal cancer (p&#x02009;&#x0003c;&#x02009;0.001). <bold>b</bold> Among 100 samples, 8 were high and 92 were low in expression of miR-138-5p. <bold>c</bold> Expression in tissues with lymph node metastasis was low, while expression in samples without lymph node metastasis was high (p&#x02009;&#x0003c;&#x02009;0.001). <bold>d</bold> Normal colonic mucosal epithelial cells were higher in expression than five colorectal cancer cell lines (p&#x02009;&#x0003c;&#x02009;0.01)
</p></caption><graphic xlink:href="12935_2020_1573_Fig1_HTML" id="d30e604"/></fig></p></sec><sec id="Sec15"><title>miR-138-5p inhibited cell migration in colorectal cancer</title><p id="Par35">For further probing the functionality of miR-138-5p in colorectal cancer cells, we knocked down its expressions in DLD1 cells and enhanced its expression in HCT116 cells. Successful knockdown of miR-138-5p could be observed in DLD1 and successful up-regulation in HCT116 cells (p&#x02009;&#x0003c;&#x02009;0.001). We screened out the best mimic and inhibitor sequences (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). To verify the effectiveness of lentivirus transfection, we performed PCR. Compared with control groups, lentiviral vectors containing miR-138-5p inhibitors (LV-inhibitor) group was lower, while the lentiviral vectors containing miR-138-5p mimics (LV-mimic) group was higher in expression of miR-138-5p (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). Knockdown treated DLD1 cells were examined by scratch test at 0&#x000a0;h and 48&#x000a0;h. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c illustrated that depleted expression of miR-138-5p significantly increased cell migration at 48&#x000a0;h. Cell migration analysis suggested knockdown treatment could increase the DLD1 cell migration (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d). In HCT116 cell lines, group of LV-mimics was lower in the percentage of cell number compared with LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). In DLD1 cell lines, group of LV-inhibitors increased the percentage of cell number compared with LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>e, f).</p><p id="Par36">
<fig id="Fig2"><label>Fig. 2</label><caption><p>
Cell migration in colorectal cancer was inhibited by miR-138-5p.&#x000a0;<bold>a</bold> The best mimic and inhibitor sequences were screened out. <bold>b</bold> Effectiveness of lentiviral transfection in DLD1 and HCT116 cell lines were verified. p&#x02009;&#x0003c;&#x02009;0.001. <bold>c</bold> Cell migration was detected by scratch experiment. <bold>d</bold> In DLD1 cell lines, LV-inhibitor group exhibited higher percentage of cell migration than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001). <bold>e</bold>, <bold>f</bold>&#x000a0;In HCT116 cell lines, the LV-mimics group was lower in the percentage of cell number compared with LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). In DLD1 cell lines, the LV-INC group was lower in the percentage of cell number compared with LV-inhibitors group (p&#x02009;&#x0003c;&#x02009;0.001)</p></caption><graphic xlink:href="12935_2020_1573_Fig2_HTML" id="d30e654"/></fig></p></sec><sec id="Sec16"><title>miR-138-5p inhibited chemotherapy resistance of colorectal cancer cells</title><p id="Par37">Three chemotherapy drugs (Fluorouracial, doxorubicin, cisplatin) were used to detect chemotherapy resistance of colorectal cancer cells. For Fluorouracial, in HCT116 cells lines, LV-mimics group was lower in relative cell viability than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a), in DLD1 cell lines, LV-inhibitor group was higher in relative cell viability than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b). For Doxorubicin, in HCT116 cells lines, LV-mimics group was lower in relative cell viability than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c), in DLD1 cell lines, LV-inhibitor group was higher in relative cell viability than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d). For Cisplatin, in HCT116 cells lines, LV-mimics group was lower in relative cell viability than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e), in DLD1 cell lines, LV-inhibitor group was higher in relative cell viability than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>f).</p><p id="Par38">
<fig id="Fig3"><label>Fig. 3</label><caption><p>
miR-138-5p could inhibit chemotherapy resistance of colorectal cancer cells.&#x000a0;<bold>a</bold> In Fluorouracial treated HCT116 cell lines, the relative cell viability of LV-mimics group was lower than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). <bold>b</bold> In Fluorouracial treated DLD1 cell lines, LV-inhibitor group was higher than LV-INC group in cell viability (p&#x02009;&#x0003c;&#x02009;0.001). <bold>c</bold> In Doxorubicin treated HCT116 cell lines, LV-mimics group was lower than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). <bold>d</bold> In Doxorubicin treated DLD1 cell lines, LV-inhibitor group was higher than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001). <bold>e</bold> In Cisplatin treated HCT116 cell lines, LV-mimics group was lower than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). <bold>f</bold> In Cisplatin treated DLD1 cell lines, LV-inhibitor group was higher than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001)
</p></caption><graphic xlink:href="12935_2020_1573_Fig3_HTML" id="d30e708"/></fig></p></sec><sec id="Sec17"><title>miR-138-5p modulated Snail1 expression, which mediated colorectal cancer cell migration and chemotherapy resistance</title><p id="Par39">We detected the relationship between miR-138-5p and Snail1 mRNA and Snail1 protein expression in 100 clinical samples. Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a showed that relative Snail1 mRNA level negatively correlated with level of miR-138-5p (p&#x02009;&#x0003c;&#x02009;0.001) Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b showed that relative Snail1 protein level negatively correlated with level of miR-138-5p (p&#x02009;&#x0003c;&#x02009;0.001). Then we examined Snail1 protein expression in stable cell lines (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c). In HCT116 cell lines, LV-mimics group was lower in the expression of Snail1 mRNA than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). In DLD1 cell lines, LV-inhibitors group was higher in the expression of Snail1 mRNA than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d). Snail1 siRNA sequences with the best interference effect was screened for subsequent experiments (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>e, f). In Fluorouracial treated DLD1 cell lines, the difference of relative cell viability between LV-inhibitor&#x02009;+&#x02009;Snail1 siRNA group and LV-INC&#x02009;+&#x02009;Snail1 siRNA group showed no statistical significance (p&#x02009;&#x0003e;&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>g). In Doxorubicin treated DLD1 cell lines, the difference of relative cell viability between LV-inhibitor&#x02009;+&#x02009;Snail1 siRNA group and LV-INC&#x02009;+&#x02009;Snail1 siRNA group displayed no significance statistically (p&#x02009;&#x0003e;&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>h) In Cisplatin treated DLD1 cell lines, the difference of relative cell viability between LV-inhibitor&#x02009;+&#x02009;Snail1 siRNA group and LV-INC&#x02009;+&#x02009;Snail1 siRNA group was not statistically significant (p&#x02009;&#x0003e;&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>i). No significant difference was observed between group LV-inhibitor&#x02009;+&#x02009;Snail1 siRNA and group LV-INC&#x02009;+&#x02009;Snail1 siRNA in terms of cell viability (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>g&#x02013;i).</p><p id="Par40">
<fig id="Fig4"><label>Fig. 4</label><caption><p>
Snail1 expression mediated colorectal cancer cell migration and chemotherapy resistance and was regulated by miR-138-5p.&#x000a0;<bold>a</bold> Relative Snail1 mRNA level negatively correlated with relative miR-138-5p level (r&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.438, p&#x02009;&#x0003c;&#x02009;0.001). <bold>b</bold> Relative Snail1 protein level negatively correlated with relative miR-138-5p level (r&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.52, p&#x02009;&#x0003c;&#x02009;0.001). <bold>c</bold> Snail1 protein expression in stable cell lines. <bold>d</bold> In HCT116 cell lines, LV-mimics group was lower in the expression of Snail1 mRNA than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). In DLD1 cell lines, LV-inhibitors group was higher in the expression of Snail1 mRNA than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001). <bold>e</bold>, <bold>f</bold> Snail1 siRNA sequences with the best interference effect was screened for subsequent experiments. <bold>g</bold>&#x000a0;In Fluorouracial treated DLD1 cell lines, the difference of relative cell viability between LV-inhibitor&#x02009;+&#x02009;Snail1 siRNA group and LV-INC&#x02009;+&#x02009;Snail1 siRNA group showed no statistical significance (p&#x02009;&#x0003e;&#x02009;0.05). <bold>h</bold>&#x000a0;In Doxorubicin treated DLD1 cell lines, the difference of relative cell viability between LV-inhibitor&#x02009;+&#x02009;Snail1 siRNA group and LV-INC&#x02009;+&#x02009;Snail1 siRNA group was not statistically significant (p&#x02009;&#x0003e;&#x02009;0.05). <bold>i</bold> In Cisplatin treated DLD1 cell lines, the difference of relative cell viability between LV-inhibitor&#x02009;+&#x02009;Snail1 siRNA group and LV-INC&#x02009;+&#x02009;Snail1 siRNA group was not statistically significant (p&#x02009;&#x0003e;&#x02009;0.05)</p></caption><graphic xlink:href="12935_2020_1573_Fig4_HTML" id="d30e780"/></fig></p></sec><sec id="Sec18"><title>miR-138-5p targeted NFIB</title><p id="Par41">Target genes were explored using three databases (DIANA, TargetScan, miRDB). NFIB was screened out based on biological function (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b illustrated that relative NFIB mRNA level negatively correlated with relative miR-138-5p level (p&#x02009;&#x0003c;&#x02009;0.05). Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>c illustrated that relative NFIB protein level negatively correlated with relative miR-138-5p level (p&#x02009;&#x0003c;&#x02009;0.05) Then we examined NFIB protein expression in stable cell lines (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>d). In HCT116 cell lines, LV-mimics group was lower in the expression of NFIB protein than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). In DLD1 cell lines, LV-inhibitors group was higher in the expression of NFIB protein than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>e). In HCT116 cell lines, LV-mimics group was lower in the expression of NFIB mRNA than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). In DLD1 cell lines, LV-inhibitors group was higher in the expression of NFIB mRNA than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>f). The wild-type and mutant plasmids of NFIB mRNA 3 UTR were constructed on the potential binding sites of miR-138-5p and NFIB mRNA (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>g). Double luciferase assay verified that miR-138-5p banded with wild type NFIB mRNA 3 UTR instead of mutant type (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>h). The NFIB siRNA with the best interference effect sequences was screened for subsequent experiments (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>i).</p><p id="Par42">
<fig id="Fig5"><label>Fig. 5</label><caption><p>
miR-138-5p targeted NFIB.&#x000a0;<bold>a</bold> Target genes of miR-138-5p were predicted by three databases, and NFIB was screened out based on biological function. <bold>b</bold> Relative NFIB mRNA level negatively correlated with relative miR-138-5p level (r&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.242, p&#x02009;&#x0003c;&#x02009;0.05). <bold>c</bold> Relative NFIB protein level negatively correlated with relative miR-138-5p level (r&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.249, p&#x02009;&#x0003c;&#x02009;0.05). <bold>d</bold> NFIB protein expression in stable cell lines. <bold>e</bold> In HCT116 cell lines, LV-mimics group was lower in the expression of NFIB protein than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). In DLD1 cell lines, LV-inhibitors group was higher in the expression of NFIB protein than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001). <bold>f</bold> In HCT116 cell lines, LV-mimics group was lower in the expression of NFIB mRNA than LV-mNC group (p&#x02009;&#x0003c;&#x02009;0.001). In DLD1 cell lines, LV-inhibitors group was higher in the expression of NFIB mRNA than LV-INC group (p&#x02009;&#x0003c;&#x02009;0.001). <bold>g</bold> The wild-type and mutant plasmids of NFIB mRNA 3 UTR were constructed on the potential binding sites of miR-138-5p and NFIB mRNA. <bold>h</bold> Double luciferase assay verified that miR-138-5p banded with wild type NFIB mRNA 3 UTR instead of mutant type (p&#x02009;&#x0003c;&#x02009;0.001). <bold>i</bold> The NFIB siRNA with the best interference effect sequences was screened for subsequent experiments</p></caption><graphic xlink:href="12935_2020_1573_Fig5_HTML" id="d30e852"/></fig></p></sec><sec id="Sec19"><title>NFIB activated Snail1</title><p id="Par43">NFIB mRNA and Snail1 mRNA expression were in positive correlation in 100 colorectal cancer tissues (p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a). In GEPIA database, NFIB mRNA and Snail1 mRNA expression were positively correlated (r&#x02009;=&#x02009;0.646, p&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b). Expression of Snail1 and NFIB after transfected with NFIB siRNA (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c). After transfected with NFIB siRNA, the relative protein level of Snail1 were decreased (p&#x02009;&#x0003c;&#x02009;0.01) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>d). After transfected with NFIB siRNA, the relative mRNA level of Snail1 were decreased (p&#x02009;&#x0003c;&#x02009;0.01) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>e). CHIP experiment verified that transcription factor NFIB could bind to the promoter region of Snail1 gene (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>f). According to the binding sites predicted by the database, wild-type and mutant plasmids of the Snail1 promoter region were constructed. Double luciferase assay experiment verified that NFIB banded to the wild-type promoter region of Snail1, instead of the mutant type (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>g&#x02013;i). Expression of Snail1 was detected after co-transfected NFIB siRNA into stable cell lines. The difference was statistically significant between NFIB siRNA-LV inhibitor&#x02009;+&#x02009;LV INC&#x02212;&#x000a0;group and NFIB siRNA-LV inhibitor-LV INC+&#x02009;group (p&#x02009;&#x0003c;&#x02009;0.001) The difference was not statistically significant between NFIB siRNA&#x02009;+&#x02009;LV inhibitor-LV INC+&#x02009;group and NFIB siRNA&#x02009;+&#x02009;LV inhibitor&#x02009;+&#x02009;LV INC&#x02212; group (p&#x02009;&#x0003e;&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>j&#x02013;k).</p><p id="Par44">
<fig id="Fig6"><label>Fig. 6</label><caption><p>
NFIB activated Snail1.&#x000a0;<bold>a</bold> NFIB mRNA and Snail1 mRNA expression had positive correlation in 100 colorectal cancer tissues (r&#x02009;=&#x02009;0.31, p&#x02009;&#x0003c;&#x02009;0.001). <bold>b</bold> In GEPIA database, NFIB mRNA and Snail1 mRNA expression were positively correlated (r&#x02009;=&#x02009;0.646, p&#x02009;&#x0003c;&#x02009;0.001). <bold>c</bold> Expression of Snail1 and NFIB after transfected with NFIB siRNA. <bold>d</bold> After transfected with NFIB siRNA, the relative protein level of Snail1 were decreased (p&#x02009;&#x0003c;&#x02009;0.01). <bold>e</bold> After transfected with NFIB siRNA, the relative mRNA level of Snail1 were decreased (p&#x02009;&#x0003c;&#x02009;0.01). <bold>f</bold> CHIP experiment verified that transcription factor NFIB could bind to the promoter region of Snail1 gene. <bold>g</bold>&#x02013;<bold>i</bold>. According to the binding sites predicted by the database, wild-type and mutant plasmids of the Snail1 promoter region were constructed. Double luciferase assay experiment verified that NFIB binded to the wild-type promoter region of Snail1, instead of the mutant type. <bold>j</bold>&#x02013;<bold>k</bold>&#x000a0;Expression of Snail1 was detected after co-transfected NFIB siRNA into stable cell lines. The difference was statistically significant between NFIB siRNA-LV inhibitor&#x02009;+&#x02009;LV INC&#x02212; group and NFIB siRNA-LV inhibitor-LV INC&#x02009;+&#x02009;group (p&#x02009;&#x0003c;&#x02009;0.001) The difference was not statistically significant between NFIB siRNA&#x02009;+&#x02009;LV inhibitor-LV INC&#x02009;+&#x02009;group and NFIB siRNA&#x02009;+&#x02009;LV inhibitor&#x02009;+&#x02009;LV INC&#x02212;&#x000a0;group (p&#x02009;&#x0003e;&#x02009;0.05)</p></caption><graphic xlink:href="12935_2020_1573_Fig6_HTML" id="d30e924"/></fig></p></sec></sec><sec id="Sec20" sec-type="discussion"><title>Discussion</title><p id="Par45">A large proportion of cancer mortality is attributed to colorectal cancer, and the incidence of colorectal cancer in younger adults has been on the rise [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Although much progress has been made to invent new treatments for combating colorectal cancer, molecular mechanisms of factors that contribute to poor prognosis such as metastasis and drug resistance are still not elucidated. Therefore, finding the key effect or that modulate colorectal cancer metastasis and drug resistance is crucial. It was notable that miR-138-5 manifested important roles in regulating tumorigenesis and progression in several types of cancers [<xref ref-type="bibr" rid="CR19">19</xref>]. As is highlighted in the literature that miR-138-5p could function as an effective tumor suppressor and monitor cell cycle. Meanwhile, it also participates in other biological processes such as neuronal development [<xref ref-type="bibr" rid="CR20">20</xref>], autophagy and so on [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par46">NFIB is a member of the nuclear factor family (which also includes NFIA, and NFIX). Emerging evidence has demonstrated that NFIB could not only participate in normal somatic development [<xref ref-type="bibr" rid="CR22">22</xref>], it also acted as an oncogene and involved in tumorigenesis of several cancers, including osteosarcoma [<xref ref-type="bibr" rid="CR23">23</xref>], glioma [<xref ref-type="bibr" rid="CR24">24</xref>], astrocytoma [<xref ref-type="bibr" rid="CR25">25</xref>], gastric cancer [<xref ref-type="bibr" rid="CR26">26</xref>], breast cancer [<xref ref-type="bibr" rid="CR27">27</xref>]. Liu et al&#x02019;s research showed that NFIB could suppress p21 transcription [<xref ref-type="bibr" rid="CR28">28</xref>]. NFIB could also mediate the accessibility of chromatin [<xref ref-type="bibr" rid="CR29">29</xref>]. The SNAIL1 gene is located in chromosome 20q.13.13. It contains three exons encoding 264 amino acids [<xref ref-type="bibr" rid="CR30">30</xref>]. Through repressing the adherent and tight junctions, Snail1 could effectively promote the epithelial&#x02013;mesenchymal transition in epithelial cells, leading to cell migratory and tumor progression [<xref ref-type="bibr" rid="CR31">31</xref>]. Emerging evidence has suggested that Snail1 acted as an important regulator of epithelial-mesenchymal transition. Snail1 could inhibit molecules such as E-cadherin and claudins (cell adhesion related), and promote cell migratory capacity. Cell adhesion, polarity and migratory properties change during epithelial&#x02013;mesenchymal transition. SNAIL1 also participates in several crucial signaling pathways, such as RTKs, TGF&#x003b2;, NOTCH, WNT, TNF &#x003b1; and BMPs pathways [<xref ref-type="bibr" rid="CR32">32</xref>]. Study by Frey et al. demonstrated that Snail1 employed canonical BMP signaling in colorectal cancer [<xref ref-type="bibr" rid="CR33">33</xref>]. Literature demonstrates that Snail1 is a key effector in modulating biological process in breast cancer [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], pancreatic cancer [<xref ref-type="bibr" rid="CR36">36</xref>], lung cancer [<xref ref-type="bibr" rid="CR37">37</xref>], glioma [<xref ref-type="bibr" rid="CR38">38</xref>], gastric cancer [<xref ref-type="bibr" rid="CR39">39</xref>], multiple myeloma [<xref ref-type="bibr" rid="CR40">40</xref>] and melanoma [<xref ref-type="bibr" rid="CR41">41</xref>]. Research also revealed that Snail1 could regulate neoangiogenesis [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par47">In our research, expression level of miR-138-5p in 100 colorectal cancer tissues and cancer cell lines were examined, and in colorectal cancer, expression was decreased. Colorectal cancer tissues with and without lymph node metastasis were studied further. Results revealed that samples without lymph node metastasis were higher in expression, which was statistically significant. Results implied that miR-138-5p participated in the down regulation of the metastasis process of colorectal cancer. Scratch test showed that by administration of miR-455-3p inhibitor, colorectal cancer cell migration was promoted, which elucidated that miR-455-3p suppressed migration of colorectal cancer cell. Fluorouracial, doxorubicin, and cisplatin were used to detect chemotherapy resistance of colorectal cancer and results indicated that chemotherapy resistance could be inhibited by miR-138-5p. In addition, the difference of cell viability of LV-inhibitor&#x02009;+&#x02009;Snail1 siRNA and LV-INC&#x02009;+&#x02009;Snail1 siRNA groups was not statistically difference. NFIB was discovered as target gene of miR-138-5p using bioinformatics methods. NFIB and Snail1 were negatively correlated with miR-138-5p, while NFIB and Snail1 were positively correlated. We performed the rescue experiments to demonstrate the interactions among miR-138-5p, NFIB and Snail1. Altogether, our study unvailed that miR-138-5p targeted the NFIB-Snail1 axis to inhibit migration and chemoresistance of colorectal cancer cells.</p><p id="Par48">In the present study, FHC was used as normal cell line. However, previous study indicated that FHC exhibited tumorigenic phenotype, complex karyotype, and TP53 gene mutation [<xref ref-type="bibr" rid="CR43">43</xref>]. Therefore, other normal colon cell lines need to be applied to validate the conclusion of this study.</p></sec><sec id="Sec21" sec-type="conclusion"><title>Conclusions</title><p id="Par49">In conclusion, we found that colorectal cancer cells were low in
expression of miR-138-5p. Through targeting NFIB-Snail1 axis miR-138-5p could regulate colorectal cancer cell migration andchemoresistance. Our research shed new light in understanding colorectal cancer migration and chemoresistance. Further research is needed for miR-138-5p to be exploited for novel treatment of colorectal cancer.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>PBS</term><def><p id="Par15">Phosphate-buffer saline</p></def></def-item><def-item><term>NC</term><def><p id="Par16">Negative control</p></def></def-item><def-item><term>LV-inhibitor</term><def><p id="Par17">Lentiviral vectors containing miR-138-5p inhibitors</p></def></def-item><def-item><term>LV-mimic</term><def><p id="Par18">Lentiviral vectors containing miR-138-5p mimics</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>WX and XC conceived and designed the project; BC and DK collected the data; WX performed the interpretation of data and statistical analysis; WX wrote the manuscript; XC revised the paper. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All data generated or analysed during this study are included in this published article.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par50">This study was approved by the ethics committee of the Affiliated Cancer Hospital of Zhengzhou University. All patients had read and signed the informed consent.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par51">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par52">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2020</article-title><source>CA Cancer J Clin</source><year>2020</year><volume>70</volume><issue>1</issue><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">31912902</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Goding Sauer</surname><given-names>A</given-names></name><name><surname>Fedewa</surname><given-names>SA</given-names></name><name><surname>Butterly</surname><given-names>LF</given-names></name><name><surname>Anderson</surname><given-names>JC</given-names></name><name><surname>Cercek</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Colorectal cancer statistics, 2020</article-title><source>CA Cancer J Clin</source><year>2020</year><volume>70</volume><issue>3</issue><fpage>145</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">32133645</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>KGM</given-names></name><name><surname>Solomon</surname><given-names>MJ</given-names></name><name><surname>Mahon</surname><given-names>K</given-names></name><name><surname>O&#x02019;Shannassy</surname><given-names>S</given-names></name></person-group><article-title>Management of colorectal cancer</article-title><source>BMJ</source><year>2019</year><volume>366</volume><fpage>l4561</fpage><pub-id pub-id-type="pmid">31439545</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>DS</given-names></name><name><surname>Berho</surname><given-names>M</given-names></name><name><surname>Perez</surname><given-names>RO</given-names></name><name><surname>Wexner</surname><given-names>SD</given-names></name><name><surname>Chand</surname><given-names>M</given-names></name></person-group><article-title>The multidisciplinary management of rectal cancer</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2020</year><volume>17</volume><issue>7</issue><fpage>414</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">32203400</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>XS</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhuang</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>XK</given-names></name><name><surname>Jiang</surname><given-names>YH</given-names></name><name><surname>Tao</surname><given-names>YN</given-names></name><name><surname>Yang</surname><given-names>CH</given-names></name></person-group><article-title>Downregulated LINC01614 ameliorates hypoxia/reoxygenation-stimulated myocardial injury by directly sponging microRNA-138-5</article-title><source>Dose Response</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>1559325820913786</fpage><pub-id pub-id-type="pmid">32231469</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Mo</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><etal/></person-group><article-title>Exosomes derived from microRNA-138-5p-overexpressing bone marrow-derived mesenchymal stem cells confer neuroprotection to astrocytes following ischemic stroke via inhibition of LCN2</article-title><source>J Biol Eng</source><year>2019</year><volume>13</volume><fpage>71</fpage><pub-id pub-id-type="pmid">31485266</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name></person-group><article-title>MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1</article-title><source>Cell Oncol</source><year>2015</year><volume>38</volume><issue>3</issue><fpage>173</fpage><lpage>81</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name></person-group><article-title>Upregulation of microRNA1385p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity</article-title><source>Mol Med Rep</source><year>2015</year><volume>12</volume><issue>4</issue><fpage>5135</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">26135834</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Lam</surname><given-names>JW</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Chen</surname><given-names>SQ</given-names></name><name><surname>Tsang</surname><given-names>RK</given-names></name><name><surname>Chan</surname><given-names>JY</given-names></name><name><surname>Wong</surname><given-names>TS</given-names></name></person-group><article-title>MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1</article-title><source>Oncol Rep</source><year>2017</year><volume>37</volume><issue>2</issue><fpage>913</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">28075468</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberto</surname><given-names>GM</given-names></name><name><surname>Lira</surname><given-names>RC</given-names></name><name><surname>Delsin</surname><given-names>LE</given-names></name><name><surname>Vieira</surname><given-names>GM</given-names></name><name><surname>Silva</surname><given-names>MO</given-names></name><name><surname>Hakime</surname><given-names>RG</given-names></name><name><surname>Yamashita</surname><given-names>ME</given-names></name><name><surname>Engel</surname><given-names>EE</given-names></name><name><surname>Scrideli</surname><given-names>CA</given-names></name><name><surname>Tone</surname><given-names>LG</given-names></name><etal/></person-group><article-title>microRNA-138-5p as a worse prognosis biomarker in pediatric, adolescent, and young adult osteosarcoma</article-title><source>Pathol Oncol Res</source><year>2020</year><volume>26</volume><issue>2</issue><fpage>877</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">30864107</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Ling</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name></person-group><article-title>MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1</article-title><source>Breast Cancer</source><year>2019</year><volume>26</volume><issue>6</issue><fpage>817</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">31243644</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Ren</surname><given-names>T</given-names></name></person-group><article-title>MiR-138-5p suppresses lung adenocarcinoma cell epithelial-mesenchymal transition, proliferation and metastasis by targeting ZEB2</article-title><source>Pathol Res Pract</source><year>2019</year><volume>215</volume><issue>5</issue><fpage>861</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">30712885</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>miRDB: an online database for prediction of functional microRNA targets</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><issue>D1</issue><fpage>D127</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">31504780</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlachos</surname><given-names>IS</given-names></name><name><surname>Vergoulis</surname><given-names>T</given-names></name><name><surname>Paraskevopoulou</surname><given-names>MD</given-names></name><name><surname>Lykokanellos</surname><given-names>F</given-names></name><name><surname>Georgakilas</surname><given-names>G</given-names></name><name><surname>Georgiou</surname><given-names>P</given-names></name><name><surname>Chatzopoulos</surname><given-names>S</given-names></name><name><surname>Karagkouni</surname><given-names>D</given-names></name><name><surname>Christodoulou</surname><given-names>F</given-names></name><name><surname>Dalamagas</surname><given-names>T</given-names></name><etal/></person-group><article-title>DIANA-mirExTra v2.0: Uncovering microRNAs and transcription factors with crucial roles in NGS expression data</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><issue>W1</issue><fpage>W128</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">27207881</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mon-Lopez</surname><given-names>D</given-names></name><name><surname>Tejero-Gonzalez</surname><given-names>CM</given-names></name></person-group><article-title>Validity and reliability of the TargetScan ISSF Pistol &#x00026; Rifle application for measuring shooting performance</article-title><source>Scand J Med Sci Sports</source><year>2019</year><volume>29</volume><issue>11</issue><fpage>1707</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">31283851</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><issue>W1</issue><fpage>W98</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">28407145</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bromham</surname><given-names>N</given-names></name><name><surname>Kallioinen</surname><given-names>M</given-names></name><name><surname>Hoskin</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>RJ</given-names></name><name><surname>Guideline</surname><given-names>C</given-names></name></person-group><article-title>Colorectal cancer: summary of NICE guidance</article-title><source>BMJ</source><year>2020</year><volume>368</volume><fpage>m461</fpage><pub-id pub-id-type="pmid">32122877</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dekker</surname><given-names>E</given-names></name><name><surname>Tanis</surname><given-names>PJ</given-names></name><name><surname>Vleugels</surname><given-names>JLA</given-names></name><name><surname>Kasi</surname><given-names>PM</given-names></name><name><surname>Wallace</surname><given-names>MB</given-names></name></person-group><article-title>Colorectal cancer</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10207</issue><fpage>1467</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">31631858</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Jiao</surname><given-names>F</given-names></name><name><surname>Yi</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>MicroRNA1385p regulates neural stem cell proliferation and differentiation in vitro by targeting TRIP6 expression</article-title><source>Mol Med Rep</source><year>2017</year><volume>16</volume><issue>5</issue><fpage>7261</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">28944841</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>K</given-names></name><name><surname>Treiber</surname><given-names>T</given-names></name><name><surname>Meister</surname><given-names>G</given-names></name><name><surname>Schratt</surname><given-names>G</given-names></name></person-group><article-title>The nuclear matrix protein Matr3 regulates processing of the synaptic microRNA-138-5</article-title><source>Neurobiol Learn Mem</source><year>2019</year><volume>159</volume><fpage>36</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">30790622</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name></person-group><article-title>Overexpression of miR-138-5p suppresses MnCl2 -induced autophagy by targeting SIRT1 in SH-SY5Y cells</article-title><source>Environ Toxicol</source><year>2019</year><volume>34</volume><issue>4</issue><fpage>539</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">30672645</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker-Santos</surname><given-names>DD</given-names></name><name><surname>Lonergan</surname><given-names>KM</given-names></name><name><surname>Gronostajski</surname><given-names>RM</given-names></name><name><surname>Lam</surname><given-names>WL</given-names></name></person-group><article-title>Nuclear Factor I/B: a master regulator of cell differentiation with paradoxical roles in cancer</article-title><source>EBioMedicine</source><year>2017</year><volume>22</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28596133</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name></person-group><article-title>LINC00319 promotes osteosarcoma progression by regulating the miR-455-3p/NFIB axis</article-title><source>J Gene Med</source><year>2020</year><pub-id pub-id-type="pmid">32926751</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name></person-group><article-title>MicroRNA-346 inhibits the growth of glioma by directly targeting NFIB</article-title><source>Cancer Cell Int</source><year>2019</year><volume>19</volume><fpage>294</fpage><pub-id pub-id-type="pmid">31807116</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>KS</given-names></name><name><surname>Bridges</surname><given-names>CR</given-names></name><name><surname>Lynton</surname><given-names>Z</given-names></name><name><surname>Lim</surname><given-names>JWC</given-names></name><name><surname>Stringer</surname><given-names>BW</given-names></name><name><surname>Rajagopal</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>KT</given-names></name><name><surname>Ganesan</surname><given-names>D</given-names></name><name><surname>Ariffin</surname><given-names>H</given-names></name><name><surname>Day</surname><given-names>BW</given-names></name><etal/></person-group><article-title>Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma</article-title><source>J Neurooncol</source><year>2020</year><volume>146</volume><issue>1</issue><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">31760595</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Ruan</surname><given-names>T</given-names></name><name><surname>Wan</surname><given-names>W</given-names></name><name><surname>Tao</surname><given-names>K</given-names></name></person-group><article-title>NFIB promotes cell growth, aggressiveness, metastasis and EMT of gastric cancer through the Akt/Stat3 signaling pathway</article-title><source>Oncol Rep</source><year>2018</year><volume>40</volume><issue>3</issue><fpage>1565</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">30015981</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>HG</given-names></name><name><surname>Hwang</surname><given-names>KT</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Jung</surname><given-names>EM</given-names></name><name><surname>Ko</surname><given-names>E</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Noh</surname><given-names>DY</given-names></name></person-group><article-title>NFIB is a potential target for estrogen receptor-negative breast cancers</article-title><source>Mol Oncol</source><year>2011</year><volume>5</volume><issue>6</issue><fpage>538</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">21925980</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>RZ</given-names></name><name><surname>Vo</surname><given-names>TM</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>WS</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Monckton</surname><given-names>EA</given-names></name><name><surname>Mackey</surname><given-names>JR</given-names></name><name><surname>Godbout</surname><given-names>R</given-names></name></person-group><article-title>NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer</article-title><source>J Pathol</source><year>2019</year><volume>247</volume><issue>2</issue><fpage>186</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">30350349</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Ruan</surname><given-names>H</given-names></name><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Nuclear factor I/B promotes colorectal cancer cell proliferation, epithelial-mesenchymal transition and 5-fluorouracil resistance</article-title><source>Cancer Sci</source><year>2019</year><volume>110</volume><issue>1</issue><fpage>86</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">30320939</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Stovall</surname><given-names>DB</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Sui</surname><given-names>G</given-names></name></person-group><article-title>The SNAIL1 promoter contains G-quadruplex structures regulating its gene expression and DNA replication</article-title><source>Exp Cell Res</source><year>2020</year><volume>2020</volume><fpage>112158</fpage></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baulida</surname><given-names>J</given-names></name><name><surname>Diaz</surname><given-names>VM</given-names></name><name><surname>Herreros</surname><given-names>AG</given-names></name></person-group><article-title>Snail1: a transcriptional factor controlled at multiple levels</article-title><source>J Clin Med</source><year>2019</year><volume>8</volume><issue>6</issue><fpage>757</fpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>A</given-names></name><name><surname>Herrera</surname><given-names>M</given-names></name><name><surname>Pena</surname><given-names>C</given-names></name></person-group><article-title>The emerging role of Snail1 in the tumor stroma</article-title><source>Clin Transl Oncol</source><year>2016</year><volume>18</volume><issue>9</issue><fpage>872</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">26687368</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>P</given-names></name><name><surname>Devisme</surname><given-names>A</given-names></name><name><surname>Schrempp</surname><given-names>M</given-names></name><name><surname>Andrieux</surname><given-names>G</given-names></name><name><surname>Boerries</surname><given-names>M</given-names></name><name><surname>Hecht</surname><given-names>A</given-names></name></person-group><article-title>Canonical BMP signaling executes epithelial-mesenchymal transition downstream of SNAIL1</article-title><source>Cancers</source><year>2020</year><volume>12</volume><issue>4</issue><fpage>1019</fpage></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maturi</surname><given-names>V</given-names></name><name><surname>Moren</surname><given-names>A</given-names></name><name><surname>Enroth</surname><given-names>S</given-names></name><name><surname>Heldin</surname><given-names>CH</given-names></name><name><surname>Moustakas</surname><given-names>A</given-names></name></person-group><article-title>Genomewide binding of transcription factor Snail1 in triple-negative breast cancer cells</article-title><source>Mol Oncol</source><year>2018</year><volume>12</volume><issue>7</issue><fpage>1153</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">29729076</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenot</surname><given-names>A</given-names></name><name><surname>Knolhoff</surname><given-names>BL</given-names></name><name><surname>DeNardo</surname><given-names>DG</given-names></name><name><surname>Longmore</surname><given-names>GD</given-names></name></person-group><article-title>SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion</article-title><source>Oncogenesis</source><year>2018</year><volume>7</volume><issue>3</issue><fpage>32</fpage><pub-id pub-id-type="pmid">29593211</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fendrich</surname><given-names>V</given-names></name><name><surname>Jendryschek</surname><given-names>F</given-names></name><name><surname>Beeck</surname><given-names>S</given-names></name><name><surname>Albers</surname><given-names>M</given-names></name><name><surname>Lauth</surname><given-names>M</given-names></name><name><surname>Esni</surname><given-names>F</given-names></name><name><surname>Heeger</surname><given-names>K</given-names></name><name><surname>Dengler</surname><given-names>J</given-names></name><name><surname>Slater</surname><given-names>EP</given-names></name><name><surname>Holler</surname><given-names>JPN</given-names></name><etal/></person-group><article-title>Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><issue>14</issue><fpage>1845</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">29367759</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>N</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Leng</surname><given-names>C</given-names></name><etal/></person-group><article-title>MiR-27b suppresses epithelial-mesenchymal transition and chemoresistance in lung cancer by targeting Snail1</article-title><source>Life Sci</source><year>2020</year><volume>254</volume><fpage>117238</fpage><pub-id pub-id-type="pmid">31887300</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Perfetto</surname><given-names>M</given-names></name><name><surname>Ping</surname><given-names>Z</given-names></name><name><surname>Christian</surname><given-names>L</given-names></name><name><surname>Niu</surname><given-names>H</given-names></name><name><surname>Mei</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>43173</fpage><pub-id pub-id-type="pmid">28256591</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer</article-title><source>Cell Death Dis</source><year>2019</year><volume>10</volume><issue>12</issue><fpage>949</fpage><pub-id pub-id-type="pmid">31827075</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1</article-title><source>Oncol Rep</source><year>2019</year><volume>41</volume><issue>1</issue><fpage>415</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">30365089</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiques</surname><given-names>O</given-names></name><name><surname>Barcelo</surname><given-names>C</given-names></name><name><surname>Panosa</surname><given-names>A</given-names></name><name><surname>Pijuan</surname><given-names>J</given-names></name><name><surname>Orgaz</surname><given-names>JL</given-names></name><name><surname>Rodriguez-Hernandez</surname><given-names>I</given-names></name><name><surname>Matas-Nadal</surname><given-names>C</given-names></name><name><surname>Tell</surname><given-names>G</given-names></name><name><surname>Vilella</surname><given-names>R</given-names></name><name><surname>Fabra</surname><given-names>A</given-names></name><etal/></person-group><article-title>T-type calcium channels drive migration/invasion in BRAFV600E melanoma cells through Snail1</article-title><source>Pigment Cell Melanoma Res</source><year>2018</year><volume>31</volume><issue>4</issue><fpage>484</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">29385656</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YK</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>YW</given-names></name><name><surname>Yue</surname><given-names>Y</given-names></name></person-group><article-title>Novel role of Snail 1 in promoting tumor neoangiogenesis</article-title><source>Biosci Rep</source><year>2019</year><pub-id pub-id-type="pmid">31868208</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soucek</surname><given-names>K</given-names></name><name><surname>Gajduskova</surname><given-names>P</given-names></name><name><surname>Brazdova</surname><given-names>M</given-names></name><name><surname>Hyzd&#x02019;alova</surname><given-names>M</given-names></name><name><surname>Koci</surname><given-names>L</given-names></name><name><surname>Vydra</surname><given-names>D</given-names></name><name><surname>Trojanec</surname><given-names>R</given-names></name><name><surname>Pernicova</surname><given-names>Z</given-names></name><name><surname>Lentvorska</surname><given-names>L</given-names></name><name><surname>Hajduch</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation</article-title><source>Cancer Genet Cytogenet</source><year>2010</year><volume>197</volume><issue>2</issue><fpage>107</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">20193843</pub-id></element-citation></ref></ref-list></back></article>